Abstract
This study was aimed to investigate the clinical efficacy of dexamethasone, methotrexate combined with cyclophosphamide for treatment of patients with peripheral T-cell lymphoma (PTCL). Twenty-one patients with peripheral T-cell lymphoma were selected as control group, which were received CHOP; twenty-nine patients with peripheral T-cell lymphoma were selected as treatment group, which were received Hyper-CVAD. Clinical efficacy were observed after treatment. In control group 6 patients achieved complete remission(CR), 4 patients achieved partial remission(PR), the total response rate of control group was 47.6%; in treatment group 15 patients achieved CR, 7 patients achieved PR, the total response rate of treatment group was 75.9%, and the total response rate of treatment group was significantly higher than that of control group. The incidence rates of cardiac dysfunction, peripheral neuropathy, anaemia and leucopenia between the two groups had no significant difference. The average progress free survival (PFS) of treatment group was 26.106 months, which was significantly higher than that of control group. The clinical efficacy of dexamethasone, methotrexate combined with cyclophosphamide for treatment of patients with peripheral T-cell lymphoma has been confirmed to be satisfactory and it may be used in clinic.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
